<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-151612" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Tapinarof</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Elder</surname>
            <given-names>Adam J.</given-names>
          </name>
          <aff>Wayne State University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Daveluy</surname>
            <given-names>Steven</given-names>
          </name>
          <aff>Wayne State University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Adam Elder declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Steven Daveluy declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>6</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-151612.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">The U.S. Food and Drug Administration (FDA) approved tapinarof in May 2022 to treat plaque psoriasis in adults aged 18 and older. Tapinarof is a nonsteroidal, topical treatment that belongs to the&#x000a0;unique class of naturally derived aryl hydrocarbon receptor (AhR) agonists, distinguishing it as the first agent of its kind and differentiating it from steroid-based treatments. Plaque psoriasis, a chronic immune-mediated disease, represents the most common subtype of psoriasis. This activity provides a comprehensive review of tapinarof, covering its indications, mechanisms of action, and administration as an effective agent for managing plaque psoriasis are discussed.&#x000a0;In addition, the activity delves into off-label uses of tapinarof, such as for treating atopic dermatitis. Various aspects of tapinarof therapy, including possible&#x000a0;adverse effects, monitoring, and potential contraindications.&#x000a0;All interprofessional healthcare team members should be aware of this information and possess a general understanding of tapinarof, as it is crucial for treating adults with plaque psoriasis.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify patients with plaque psoriasis for potential eligibility and suitability for tapinarof treatment, considering factors such as age, comorbidities, disease severity, treatment history, and patient preferences.</p></list-item><list-item><p>Screen patients for contraindications, potential drug interactions, and other factors that may impact the safe and effective use of tapinarof to ensure the appropriate patient selection and treatment safety.</p></list-item><list-item><p>Assess the effectiveness of tapinarof in managing plaque psoriasis by monitoring patient and treatment response, evaluating disease severity, assessing adverse effects, and adjusting the treatment plan as needed.</p></list-item><list-item><p>Collaborate with other healthcare professionals, such as dermatologists, rheumatologists, and primary care physicians, to ensure coordinated care and optimize treatment outcomes for patients using tapinarof.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=151612&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=151612">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-151612.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>In May 2022, the U.S. Food and Drug Administration (FDA) approved tapinarof for treating plaque psoriasis in adults aged 18 and older. Plaque psoriasis, the most prevalent subtype of psoriasis, is a chronic immune-mediated disease characterized by scaly, erythematous plaques that are often itchy or painful. Tapinarof, alternatively known as 3,5-dihydroxy-4-isopropyl-<italic toggle="yes">trans-s</italic>tilbene or (E)-2-isopropyl-5-styrylbenzene-1,3-diol, is a treatment derived from bacteria.<xref ref-type="bibr" rid="article-151612.r1">[1]</xref></p>
        <p>Psoriasis can manifest in different anatomical regions,&#x000a0;with the extensor surfaces, such as the elbows and knees, being the most frequently&#x000a0;affected areas. This systemic inflammatory condition impacts many individuals, exceeding 100 million men and women, and is linked to numerous comorbidities. The associated comorbidities include psoriatic arthritis (PsA), cardiovascular disease, metabolic syndrome, obesity, hypertension, diabetes, kidney disease, malignancy, inflammatory bowel disease, and psychiatric disorders.<xref ref-type="bibr" rid="article-151612.r2">[2]</xref>&#x000a0;</p>
        <p>The pathogenesis of psoriasis is believed to be attributed to the overexpression of critical factors within the adaptive immune system. Initially, dendritic cells activate and release interleukins (IL), specifically IL-12 and IL-23. IL-12 stimulates the differentiation of Th1 cells, whereas IL-23 promotes the differentiation of TH17 T cells. In plaque psoriasis, the primary pathway involves the IL-23&#x02013;mediated activation of Th17 T cells, resulting in the secretion of cytokines such as IL-17, IL-22, and tumor necrosis factor-alpha (TNF-&#x003b1;). This release of cytokines by immune cells disrupts the skin's homeostasis, leading to inflammation and increased proliferation of keratinocytes, which are the characteristic features of psoriasis.<xref ref-type="bibr" rid="article-151612.r3">[3]</xref><xref ref-type="bibr" rid="article-151612.r4">[4]</xref><xref ref-type="bibr" rid="article-151612.r5">[5]</xref></p>
        <p>Psoriasis, being an inflammatory dermatosis, imposes considerable discomfort on patients. Individuals with plaque psoriasis often adjust their clothing choices and dietary habits to seek relief and comfort for their skin and avoid triggering psoriatic flare-ups. This condition can also restrict the daily activities of individuals, profoundly affecting their quality of life and mental well-being. The psychological impact is important in the long-term care of patients with psoriasis. Studies have proven&#x000a0;that stress is a significant risk factor capable of exacerbating and even inducing psoriatic flares.<xref ref-type="bibr" rid="article-151612.r6">[6]</xref>&#x000a0;</p>
        <p>In addition to the physiological impact, stress can also arise from the social and physical consequences of psoriasis, which can intensify the condition's symptoms. Individuals with psoriasis are at a higher risk of developing a negative body image and experiencing lower self-esteem due to the presence of visible skin lesions. Patients with plaque psoriasis often experience stigmatization from individuals who lack adequate knowledge about this condition and are unaware that&#x000a0;psoriasis is noncontagious. Psoriasis can significantly diminish the quality of life of patients who have to deal with this condition, making them more vulnerable to depression and thoughts of self-harm or suicide.<xref ref-type="bibr" rid="article-151612.r7">[7]</xref><xref ref-type="bibr" rid="article-151612.r8">[8]</xref></p>
        <p>Numerous treatments have been developed to effectively manage psoriasis, including immune-modulating therapy, topical corticosteroids and vitamin D analogs, phototherapy, small-molecule inhibitors, and biologics.<xref ref-type="bibr" rid="article-151612.r9">[9]</xref> Tapinarof cream is a distinctive nonsteroidal topical treatment that offers convenience to patients while targeting a novel pathway distinct from existing therapies for plaque psoriasis.&#x000a0;Notably, tapinarof is the first topical treatment approved for plaque psoriasis in several decades. Traditionally, vitamin D analogs and corticosteroids have been the primary topical options for managing plaque psoriasis over the years.<xref ref-type="bibr" rid="article-151612.r10">[10]</xref>&#x000a0;With the additional advantage of once-daily administration, tapinarof has proven to be a highly effective topical treatment for psoriasis, exhibiting minimal side effects and imposing limited restrictions on its usage.</p>
        <p>In 2 identically designed phase&#x000a0;III trials, namely PSOARING 1 and 2 trials, which were randomized, vehicle-controlled, double-blind, and multicenter, the efficacy of tapinarof cream 1% administered once daily was demonstrated. These trials spanned a duration of 12 weeks and exhibited a significant reduction in the severity of plaque psoriasis.<xref ref-type="bibr" rid="article-151612.r11">[11]</xref>&#x000a0;The primary endpoint for each trial was defined as a PGA (Physician Global Assessment) score response of either 0 (clear) or 1 (almost clear), in addition to a minimum decrease of 2 points at week 12 compared to the baseline. In trial 1, the results revealed a 35.4% primary endpoint response for patients in the tapinarof group, whereas the vehicle-controlled group exhibited a response of 6.0%. Similarly, trial&#x000a0;2&#x000a0;concluded with a PGA response observed in 40.2% of patients in the tapinarof group, whereas the vehicle-controlled group had a response of 6.3%.<xref ref-type="bibr" rid="article-151612.r11">[11]</xref>&#x000a0;</p>
        <p>In the PSOARING 3 trial (open-label extension study), tapinarof cream 1%, administered daily exhibited sustained improvement in efficacy beyond the levels observed in the pivotal trials. Furthermore, the drug was well tolerated for up to 52 weeks during the long-term treatment. This trial demonstrated a significant rate of complete disease clearance, with 40.9% of patients achieving this outcome. Moreover, tapinarof showed the ability to maintain the response over time and had a remitting effect that lasted for approximately 4 months even after discontinuing the therapy. Importantly, tachyphylaxis, associated with topical corticosteroids and biologics, was not observed with tapinarof within the 52-week time frame.<xref ref-type="bibr" rid="article-151612.r12">[12]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Tapinarof entered phase 3 clinical trials in August 2021 to treat atopic dermatitis (AD). AD is a cutaneous inflammatory condition also referred to as eczema. Unlike psoriasis, AD typically manifests on flexor surfaces such as the antecubital and popliteal fossae. The inflammation is characterized by a type 1 hypersensitivity reaction, which is associated with elevated levels of immunoglobulin E (IgE). Mutations in the filaggrin gene often cause skin barrier dysfunction. The activation of Th2 T cells primarily drives the inflammatory response in AD. The predominance of Th2 T cells results in elevated levels of Th2-released cytokines, including IL-4 and IL-13, both of which promote IgE production. IL-4 also promotes further differentiation of helper T cells into the Th2 subtype.<xref ref-type="bibr" rid="article-151612.r13">[13]</xref><xref ref-type="bibr" rid="article-151612.r14">[14]</xref>&#x000a0;</p>
        <p>Previous phase 2b trials yielded positive results, paving the way for this double-blind, randomized, vehicle-controlled, multicenter phase 2b study. In this study, adolescents older than 12 and adults diagnosed with AD were randomly assigned in a 1:1:1:1:1:1 ratio to&#x000a0;receive any 1 of the&#x000a0;2 treatments for 12 weeks: tapinarof cream (0.5% or 1% concentration) applied either once or twice daily, or a vehicle cream used once or twice daily.&#x000a0;The primary efficacy endpoint was measured utilizing the IGA (Investigator Global Assessment) scale, indicating outcomes defined as a score of either 0 (clear) or 1 (almost clear), along with a minimum decrease of 2 points at week 12 compared to the baseline.</p>
        <p>The study results demonstrated varying IGA response rates within each group, as depicted in Table 1.</p>
        <table-wrap id="article-151612.table0" position="float" orientation="portrait">
          <caption>
            <title>Table 1.&#x000a0;IGA Response Rates for Tapinarof in the Treatment of AD</title>
          </caption>
          <table style="width: 471px; border-color: black; height: 136px;" border="black">
            <tbody>
              <tr>
                <td style="width: 109.042px;" rowspan="1" colspan="1">
<p>&#x000a0;<bold>Frequencies</bold></p>
</td>
                <td style="width: 132.219px;" rowspan="1" colspan="1">
<p><bold>Tapinarof (1%)</bold></p>
</td>
                <td style="width: 123.729px;" rowspan="1" colspan="1">
<p><bold>Tapinarof (0.5%)</bold></p>
</td>
                <td style="width: 81.3438px;" rowspan="1" colspan="1">
<p><bold>Vehicle</bold></p>
</td>
              </tr>
              <tr>
                <td style="width: 109.042px;" rowspan="1" colspan="1">
<p>Twice Daily</p>
</td>
                <td style="width: 132.219px;" rowspan="1" colspan="1">
<p>53% (<italic toggle="yes">P</italic>&#x000a0;= .008)</p>
</td>
                <td style="width: 123.729px;" rowspan="1" colspan="1">
<p>37% (<italic toggle="yes">P</italic>&#x000a0;= .240)</p>
</td>
                <td style="width: 81.3438px;" rowspan="1" colspan="1">
<p>24%</p>
</td>
              </tr>
              <tr>
                <td style="width: 109.042px;" rowspan="1" colspan="1">
<p>Once Daily</p>
</td>
                <td style="width: 132.219px;" rowspan="1" colspan="1">
<p>46% (<italic toggle="yes">P</italic>&#x000a0;= .084)</p>
</td>
                <td style="width: 123.729px;" rowspan="1" colspan="1">
<p>34% (<italic toggle="yes">P</italic>&#x000a0;= .535)</p>
</td>
                <td style="width: 81.3438px;" rowspan="1" colspan="1">
<p>28%</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>Tapinarof 1% concentration demonstrated the highest IGA response rate, especially when administered twice daily. The primary analysis of the phase 2b study provided evidence of tapinarof's efficacy in treating adolescents and adults with AD. These findings suggest that tapinarof cream has the potential to be an effective topical treatment for individuals with AD. However, further well-designed phase&#x000a0;3 studies are necessary to solidify these results.<xref ref-type="bibr" rid="article-151612.r15">[15]</xref><xref ref-type="bibr" rid="article-151612.r16">[16]</xref></p>
        <p>Both psoriasis and AD are prevalent cutaneous inflammatory conditions. Recent studies have revealed that more than 80% of the dysfunctional genes implicated in psoriasis lesions are also involved in AD skin lesions, highlighting shared genetic factors, despite the distinct characteristics of the 2 conditions. Hence, the efficacy of tapinarof in treating both AD and psoriasis is not unusual.<xref ref-type="bibr" rid="article-151612.r17">[17]</xref></p>
      </sec>
      <sec id="article-151612.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Tapinarof is a naturally derived&#x000a0;aryl hydrocarbon receptor (AhR) agonist and the first topical treatment of its kind. The AhR, a ligand-dependent transcription factor, functions as an environmental sensor expressed in keratinocytes and other cells, contributing to maintaining skin homeostasis.<xref ref-type="bibr" rid="article-151612.r4">[4]</xref><xref ref-type="bibr" rid="article-151612.r18">[18]</xref></p>
        <p>Tapinarof binds to and activates AhR, inducing gene expression, resulting in the following effects:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Downregulation of pro-inflammatory cytokines, including IL-17, which is involved in the pathogenesis of psoriasis, and IL-4 and IL-13, which are involved in the pathogenesis of AD. This leads to an overall decrease in skin inflammation.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Restoration of the dysfunctional skin barrier by inducing the expression of essential skin barrier proteins, such as filaggrin and loricrin,&#x000a0;along with other crucial components.</p>
          </list-item>
          <list-item>
            <p>Enhancement of the antioxidant response mediated by Nrf2, which is a transcription factor that regulates the defenses against oxidative stress.&#x000a0;</p>
          </list-item>
        </list>
        <p>Recent investigations have highlighted AhR's immune modulatory potential, suggesting its involvement in various systemic diseases, such as asthma, multiple sclerosis, rheumatoid arthritis, allergic reactions, and more.<xref ref-type="bibr" rid="article-151612.r19">[19]</xref> As a nuclear transcription factor, AhR is dependent on ligand binding for activation, which subsequently alters gene expression when activated. Although tapinarof&#x000a0;is&#x000a0;an AhR ligand, the nuclear receptor can bind to other diverse ligands. Each ligand may stimulate the receptor to generate a similar but distinctive response. Notable examples of other AhR ligands include tryptophan, tryptamine, norisoboldine, kynurenine, and diindolylmethane.<xref ref-type="bibr" rid="article-151612.r20">[20]</xref> The altered gene regulation and expression pathways can vary depending on the ligand that activates AhR.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Absorption:&#x000a0;Tapinarof shows no evidence of site-specific accumulation when used continuously.</p>
          </list-item>
          <list-item>
            <p>Distribution:&#x000a0;The plasma concentration of tapinarof remains consistently below the detection limit.</p>
          </list-item>
          <list-item>
            <p>Metabolism: In vitro studies have demonstrated that tapinarof has a high binding affinity (99%) to plasma proteins and undergoes hepatic metabolism primarily through oxidation, sulfation, and glucuronide conjugation reactions. Tapinarof does not modulate the activity of cytochrome P450 enzymes or transporters.<xref ref-type="bibr" rid="article-151612.r4">[4]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-151612.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms</bold>
</p>
        <p>Tapinarof topical cream with a concentration of 1%.</p>
        <p>
<bold>Strength</bold>
</p>
        <p>Each gram of the topical cream formulation contains 10 mg of tapinarof.</p>
        <p>Tapinarof is a nonsteroidal, topical treatment available as a 1% cream formulation specifically designed to be administered once daily to manage plaque psoriasis.<xref ref-type="bibr" rid="article-151612.r4">[4]</xref> The cream formula should be directly applied to the psoriatic plaques and gently massaged until fully absorbed into the skin. Patients should be informed that visible improvement in plaque psoriasis may take several weeks; therefore, patients need to use&#x000a0;tapinarof consistently and regularly as their healthcare provider prescribes. Tapinarof topical cream is not intended for oral, vaginal, or ophthalmic use. Patients should be advised to thoroughly cleanse their hands after the tapinarof application, except the treatment areas on the hands.<xref ref-type="bibr" rid="article-151612.r18">[18]</xref></p>
        <p>
<bold>Specific Patient Population</bold>
</p>
        <p>Patients with hepatic impairment: The FDA-approved product labeling does not provide dosage adjustment information for tapinarof in patients with hepatic impairment.</p>
        <p>Patients with renal impairment: The FDA-approved product labeling also does not provide dosage adjustment information for tapinarof in patients with renal impairment.</p>
        <p>Pregnancy considerations:&#x000a0;Limited clinical data are available concerning the use of tapinarof cream in pregnant women, making it difficult to assess the potential risks of congenital disabilities, miscarriage, or other adverse outcomes for both the mother and fetus. However, animal studies involving pregnant rats and rabbits demonstrated no significant adverse effects when tapinarof was administered subcutaneously during the organogenesis phase. These studies used doses up to 268 and 16 times higher than the maximum recommended human dose (MRHD).</p>
        <p>Breastfeeding considerations:&#x000a0;The safety of tapinarof during breastfeeding has not been specifically studied. However, due to its poor absorption after topical application, it is generally believed to pose a low risk to the nursing infant. To further minimize potential exposure, it is essential to avoid applying tapinarof cream directly to the areola and nipple. Clinicians should educate mothers about ensuring that the treated skin areas do not come into direct contact with the infant's skin, further reducing potential risk.<xref ref-type="bibr" rid="article-151612.r21">[21]</xref></p>
        <p>Pediatric patients:&#x000a0;The safety and efficacy of tapinarof&#x000a0;have not been established in pediatric patients with psoriasis who are younger than 18.</p>
        <p>Geriatric patients:&#x000a0;Clinical trials have concluded that there are no differences in the efficacy or safety of tapinarof cream between older patients and younger adults.<xref ref-type="bibr" rid="article-151612.r4">[4]</xref><xref ref-type="bibr" rid="article-151612.r11">[11]</xref></p>
      </sec>
      <sec id="article-151612.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Adverse Drug Reactions</bold>
</p>
        <p>Adverse effects with topical tapinarof treatment are rare, with most patients experiencing no adverse effects during tapinarof treatment.<xref ref-type="bibr" rid="article-151612.r22">[22]</xref>&#x000a0;</p>
        <p>The most commonly reported adverse effects of topical tapinarof are listed below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Folliculitis (or inflammation around hair follicles), occuring at the tapinarof application site.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Headaches, including general headaches, tension headaches, and migraines.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Pruritis, including genital pruritis, tapinarof application site pruritis, and generalized pruritis.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Contact dermatitis, including hand dermatitis, generalized rashes, urticaria, and skin peeling.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Nasopharyngitis, including pharyngitis, nasal congestion, and rhinorrhea.</p>
          </list-item>
          <list-item>
            <p>Upper respiratory tract infections, including influenza and flu-like symptoms.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Localized back pain.<xref ref-type="bibr" rid="article-151612.r23">[23]</xref><xref ref-type="bibr" rid="article-151612.r12">[12]</xref></p>
          </list-item>
        </list>
        <p>In most studies assessing the safety and efficacy of topical tapinarof, most patients could continue the treatment despite an adverse reaction. In the PSOARING 3 trials, low trial discontinuation rates of 1.2% and 1.4% were observed for folliculitis and contact dermatitis, respectively. These results were similar to those found in the PSOARING&#x000a0;1 and&#x000a0;2 trials.<xref ref-type="bibr" rid="article-151612.r22">[22]</xref><xref ref-type="bibr" rid="article-151612.r24">[24]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Tapinarof is devoid of drug-drug interactions. Topical tapinarof cream does not inhibit or induce the cytochrome P450 superfamily of enzymes, including CYP3A4, CYP2C9, CYP2B6, or CYP1A2.<xref ref-type="bibr" rid="article-151612.r18">[18]</xref><xref ref-type="bibr" rid="article-151612.r25">[25]</xref> Furthermore, tapinarof does not inhibit various transport systems, including the organic anion family of transporters (OAT), organic cation family of transporters (OCT), multidrug and toxic compound extrusion (MATE) family of transporters, or the breast cancer resistance transporter (BCRP).<xref ref-type="bibr" rid="article-151612.r18">[18]</xref><xref ref-type="bibr" rid="article-151612.r25">[25]</xref></p>
      </sec>
      <sec id="article-151612.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>There are no known contraindications for the topical use of tapinarof in treating plaque psoriasis except for individuals with a known sensitivity to the drug or formulation ingredients. Tapinarof topical treatment has not been approved for patients younger than 18.<xref ref-type="bibr" rid="article-151612.r12">[12]</xref>&#x000a0;</p>
        <p>
<bold>Precautions</bold>
</p>
        <p>Research has not yet determined whether&#x000a0;tapinarof cream can cause harm to pregnant patients or cause defects in fetal growth and development. Furthermore, the potential transmission of tapinarof through lactation from breastfeeding mothers to infants is yet to be determined. Further research is needed to assess whether tapinarof can pose any potential harm to nursing infants.<xref ref-type="bibr" rid="article-151612.r12">[12]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-151612.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Treatment with topical tapinarof does not necessitate routine monitoring. However, patients are advised to contact their dermatologist if they encounter any adverse effects during the course of treatment.</p>
      </sec>
      <sec id="article-151612.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Symptoms and Management of Overdose</bold>
</p>
        <p>Tapinarof has exhibited a favorable safety profile and is generally well tolerated.<xref ref-type="bibr" rid="article-151612.r10">[10]</xref> Throughout the phase&#x000a0;3 trials, PSOARING 1 and 2 trials, safety and efficacy assessments revealed no significant differences among&#x000a0;the tapinarof and control groups regarding changes in vital signs, laboratory values, or electrocardiogram readings. Notably, tachyphylaxis, associated with topical corticosteroids and biologics, was not observed with tapinarof within the 52-week time frame.<xref ref-type="bibr" rid="article-151612.r12">[12]</xref></p>
        <p>Furthermore, sensitive application areas, including the skin folds and face, have shown good tolerance to tapinarof. To facilitate a comprehensive comparison with older treatments for plaque psoriasis, it is essential to conduct longer trials that further assess the safety and efficacy of tapinarof cream.<xref ref-type="bibr" rid="article-151612.r11">[11]</xref></p>
      </sec>
      <sec id="article-151612.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>A cross-sectional study suggests that psoriasis is a prevalent, immune-mediated condition, affecting 3% of the adult population in the United States, indicating a substantial disease burden.<xref ref-type="bibr" rid="article-151612.r26">[26]</xref> Tapinarof is prescribed to adults with plaque psoriasis to assist patients in managing their condition and, therefore, enhancing their quality of life. Plaque psoriasis is associated with multiple comorbidities and can contribute to low self-esteem, leading to a decline in patients' overall quality of life.</p>
        <p>Some of the most common comorbidities associated with psoriasis include PsA, cardiovascular disease, mental health disorders, and metabolic syndrome. Guidelines, such as the joint American Academy of Dermatology (AAD)-National Psoriasis Foundation (NPF), have been established to aid clinicians in effectively screening and managing these associated comorbidities. The AAD-NPF care guidelines emphasize the importance of vigilance and awareness regarding psoriatic comorbidities, offering recommendations and strategies for physicians to follow in providing comprehensive patient care.<xref ref-type="bibr" rid="article-151612.r27">[27]</xref>&#x000a0;</p>
        <p>According to these guidelines, when screening patients for PsA, the initial recommendation (1.1) is to inform patients about the association between psoriasis and PsA. Recommendation 1.2 states that all patients with cutaneous psoriasis should be evaluated for the presence of PsA, and this screening should be conducted at every clinic visit. In addition, recommendation 1.3 states that patients showing signs or symptoms of PsA should undergo a comprehensive evaluation for PsA, and appropriate therapy should be initiated if the dermatologist is comfortable with the diagnosis. Rheumatology consultation can be sought to confirm the diagnosis of PsA and provide assistance in its assessment and management.<xref ref-type="bibr" rid="article-151612.r27">[27]</xref>&#x000a0;</p>
        <p>Guidelines for clinicians have been established to address most psoriasis-associated comorbidities, which are essential in the comprehensive and collaborative management of patients with psoriasis. For instance, the cooperation between rheumatologists and dermatologists is essential in confirming diagnoses and providing the best possible management for both psoriasis and comorbid PsA. Similarly, the collaboration of dermatologists with primary care physicians or cardiology specialists is crucial, given psoriasis's associations with hypertension, diabetes, and hyperlipidemia.<xref ref-type="bibr" rid="article-151612.r27">[27]</xref> These guidelines ensure appropriate referrals when necessary and foster an inclusive collaboration among all interprofessional healthcare team members, ultimately delivering optimal quality of care for patients.</p>
        <p>The interprofessional healthcare team includes clinicians and pharmacists, requiring collaboration and communication to ensure consistent knowledge and comprehension. A positive relationship between a patient and clinician is crucial for promoting a healthy patient mindset and mental well-being. The interprofessional healthcare team can&#x000a0;enhance patient care by providing valuable input and leveraging their expertise. Patients with plaque psoriasis often experience a sense of diminished control over their condition and daily lives. Hence, the interprofessional team must empower patients by fostering a perception of control and showcasing the collaborative efforts of all team members in providing optimal care. This approach will further strengthen the patient-clinician relationship and improve health outcomes for patients with plaque psoriasis&#x000a0;undergoing tapinarof treatment.<xref ref-type="bibr" rid="article-151612.r28">[28]</xref></p>
      </sec>
      <sec id="article-151612.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=151612&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=151612">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/151612/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=151612">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-151612.s11">
        <title>References</title>
        <ref id="article-151612.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johnston</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Resolving Inflammation by Targeting an Ancient Innate Immune Sensor with a Bacterial Metabolite.</article-title>
            <source>J Invest Dermatol</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>137</volume>
            <issue>10</issue>
            <fpage>2050</fpage>
            <page-range>2050-2052</page-range>
            <pub-id pub-id-type="pmid">28941474</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151612.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takeshita</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Grewal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Langan</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>NN</given-names>
              </name>
              <name>
                <surname>Ogdie</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Van Voorhees</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Gelfand</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Psoriasis and comorbid diseases: Epidemiology.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>76</volume>
            <issue>3</issue>
            <fpage>377</fpage>
            <page-range>377-390</page-range>
            <pub-id pub-id-type="pmid">28212759</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151612.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Armstrong</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Read</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review.</article-title>
            <source>JAMA</source>
            <year>2020</year>
            <month>May</month>
            <day>19</day>
            <volume>323</volume>
            <issue>19</issue>
            <fpage>1945</fpage>
            <page-range>1945-1960</page-range>
            <pub-id pub-id-type="pmid">32427307</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151612.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jett</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>McLaughlin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Parish</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>DuBois</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Raoof</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Tabolt</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Somerville</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>DellaMaestra</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Piscitelli</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Tapinarof Cream 1% for Extensive Plaque Psoriasis: A Maximal Use Trial on Safety, Tolerability, and Pharmacokinetics.</article-title>
            <source>Am J Clin Dermatol</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>83</fpage>
            <page-range>83-91</page-range>
            <pub-id pub-id-type="pmid">34713415</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151612.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alwan</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Nestle</surname>
                <given-names>FO</given-names>
              </name>
            </person-group>
            <article-title>Pathogenesis and treatment of psoriasis: exploiting pathophysiological pathways for precision medicine.</article-title>
            <source>Clin Exp Rheumatol</source>
            <year>2015</year>
            <season>Sep-Oct</season>
            <volume>33</volume>
            <issue>5 Suppl 93</issue>
            <fpage>S2</fpage>
            <page-range>S2-6</page-range>
            <pub-id pub-id-type="pmid">26472336</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151612.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Basavaraj</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Navya</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Rashmi</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Stress and quality of life in psoriasis: an update.</article-title>
            <source>Int J Dermatol</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>50</volume>
            <issue>7</issue>
            <fpage>783</fpage>
            <page-range>783-92</page-range>
            <pub-id pub-id-type="pmid">21699511</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151612.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kouris</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Platsidaki</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kouskoukis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Christodoulou</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Psychological parameters of psoriasis.</article-title>
            <source>Psychiatriki</source>
            <year>2017</year>
            <season>Jan-Mar</season>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>54</fpage>
            <page-range>54-59</page-range>
            <pub-id pub-id-type="pmid">28541239</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151612.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Van Voorhees</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Fried</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Depression and quality of life in psoriasis.</article-title>
            <source>Postgrad Med</source>
            <year>2009</year>
            <month>Jul</month>
            <volume>121</volume>
            <issue>4</issue>
            <fpage>154</fpage>
            <page-range>154-61</page-range>
            <pub-id pub-id-type="pmid">19641281</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151612.r9">
          <label>9</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Badri</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Oakley</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <chapter-title>Plaque Psoriasis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">28613629</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151612.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jett</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McLaughlin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Somerville</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>DellaMaestra</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Rubenstein</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Piscitelli</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Dermal Safety of Tapinarof Cream 1%: Results From 4 Phase 1 Trials.</article-title>
            <source>J Drugs Dermatol</source>
            <year>2022</year>
            <month>Oct</month>
            <day>01</day>
            <volume>21</volume>
            <issue>10</issue>
            <fpage>1084</fpage>
            <page-range>1084-1090</page-range>
            <pub-id pub-id-type="pmid">36219046</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151612.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lebwohl</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Stein Gold</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Strober</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Papp</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Armstrong</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Bagel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kircik</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ehst</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Soung</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fromowitz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Guenthner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Piscitelli</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Rubenstein</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Tallman</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Bissonnette</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis.</article-title>
            <source>N Engl J Med</source>
            <year>2021</year>
            <month>Dec</month>
            <day>09</day>
            <volume>385</volume>
            <issue>24</issue>
            <fpage>2219</fpage>
            <page-range>2219-2229</page-range>
            <pub-id pub-id-type="pmid">34879448</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151612.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strober</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Stein Gold</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bissonnette</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Armstrong</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Kircik</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tyring</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Piscitelli</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Rubenstein</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Tallman</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Lebwohl</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING&#x000a0;3 trial.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>87</volume>
            <issue>4</issue>
            <fpage>800</fpage>
            <page-range>800-806</page-range>
            <pub-id pub-id-type="pmid">35772599</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151612.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kleinman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Laborada</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Metterle</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Eichenfield</surname>
                <given-names>LF</given-names>
              </name>
            </person-group>
            <article-title>What's New in Topicals for Atopic Dermatitis?</article-title>
            <source>Am J Clin Dermatol</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>23</volume>
            <issue>5</issue>
            <fpage>595</fpage>
            <page-range>595-603</page-range>
            <pub-id pub-id-type="pmid">36048410</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151612.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>David Boothe</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Tarbox</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Tarbox</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>Atopic Dermatitis: Pathophysiology.</article-title>
            <source>Adv Exp Med Biol</source>
            <year>2017</year>
            <volume>1027</volume>
            <fpage>21</fpage>
            <page-range>21-37</page-range>
            <pub-id pub-id-type="pmid">29063428</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151612.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paller</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Stein Gold</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Soung</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tallman</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Rubenstein</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Gooderham</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>84</volume>
            <issue>3</issue>
            <fpage>632</fpage>
            <page-range>632-638</page-range>
            <pub-id pub-id-type="pmid">32502588</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151612.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bissonnette</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Saint-Cyr Proulx</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Jack</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Maari</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Tapinarof for psoriasis and atopic dermatitis: 15&#x02009;years of clinical research.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2023</year>
            <month>Jun</month>
            <volume>37</volume>
            <issue>6</issue>
            <fpage>1168</fpage>
            <page-range>1168-1174</page-range>
            <pub-id pub-id-type="pmid">36708084</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151612.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Furue</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hashimoto-Hachiya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tsuji</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Aryl Hydrocarbon Receptor in Atopic Dermatitis and Psoriasis.</article-title>
            <source>Int J Mol Sci</source>
            <year>2019</year>
            <month>Oct</month>
            <day>31</day>
            <volume>20</volume>
            <issue>21</issue>
            <pub-id pub-id-type="pmid">31683543</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151612.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Keam</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Tapinarof Cream 1%: First Approval.</article-title>
            <source>Drugs</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>82</volume>
            <issue>11</issue>
            <fpage>1221</fpage>
            <page-range>1221-1228</page-range>
            <pub-id pub-id-type="pmid">35939180</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151612.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>He</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ru</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wen</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>NRF2, a Transcription Factor for Stress Response and Beyond.</article-title>
            <source>Int J Mol Sci</source>
            <year>2020</year>
            <month>Jul</month>
            <day>06</day>
            <volume>21</volume>
            <issue>13</issue>
            <pub-id pub-id-type="pmid">32640524</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151612.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Neavin</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ray</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Weinshilboum</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>The Role of the Aryl Hydrocarbon Receptor (AHR) in Immune and Inflammatory Diseases.</article-title>
            <source>Int J Mol Sci</source>
            <year>2018</year>
            <month>Dec</month>
            <day>03</day>
            <volume>19</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">30513921</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151612.r21">
          <label>21</label>
          <element-citation publication-type="book">
            <chapter-title>Tapinarof</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2024</year>
            <month>2</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">36701502</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151612.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nogueira</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rodrigues</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Vender</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Torres</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Tapinarof for the treatment of psoriasis.</article-title>
            <source>Dermatol Ther</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>35</volume>
            <issue>12</issue>
            <fpage>e15931</fpage>
            <pub-id pub-id-type="pmid">36226669</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151612.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bissonnette</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vasist</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Bullman</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Collingwood</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Maeda-Chubachi</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Systemic Pharmacokinetics, Safety, and Preliminary Efficacy of Topical AhR Agonist Tapinarof: Results of a Phase 1 Study.</article-title>
            <source>Clin Pharmacol Drug Dev</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>7</volume>
            <issue>5</issue>
            <fpage>524</fpage>
            <page-range>524-531</page-range>
            <pub-id pub-id-type="pmid">29389078</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151612.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Konstantinou</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Jendoubi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hegazy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bouznad</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tauber</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bulai-Livideanu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Paul</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Tapinarof-induced folliculitis: The paradigm of activation of the aryl hydrocarbon signaling pathway.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>85</volume>
            <issue>1</issue>
            <fpage>e37</fpage>
            <page-range>e37-e38</page-range>
            <pub-id pub-id-type="pmid">33677000</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151612.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cai</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>QJ</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>YZ</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>FQ</given-names>
              </name>
              <name>
                <surname>Xiao</surname>
                <given-names>SX</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>QN</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>XH</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Hao</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>QZ</given-names>
              </name>
              <name>
                <surname>Tu</surname>
                <given-names>YT</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>RY</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>BX</given-names>
              </name>
              <name>
                <surname>Deng</surname>
                <given-names>DQ</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>QS</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>HX</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>JZ</given-names>
              </name>
            </person-group>
            <article-title>A double-blind, randomized, placebo- and positive-controlled phase III trial of 1% benvitimod cream in mild-to-moderate plaque psoriasis.</article-title>
            <source>Chin Med J (Engl)</source>
            <year>2020</year>
            <month>Nov</month>
            <day>09</day>
            <volume>133</volume>
            <issue>24</issue>
            <fpage>2905</fpage>
            <page-range>2905-2909</page-range>
            <pub-id pub-id-type="pmid">33177393</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151612.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Armstrong</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Schupp</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Gondo</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Griffiths</surname>
                <given-names>CEM</given-names>
              </name>
            </person-group>
            <article-title>Psoriasis Prevalence in Adults in the United States.</article-title>
            <source>JAMA Dermatol</source>
            <year>2021</year>
            <month>Aug</month>
            <day>01</day>
            <volume>157</volume>
            <issue>8</issue>
            <fpage>940</fpage>
            <page-range>940-946</page-range>
            <pub-id pub-id-type="pmid">34190957</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151612.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elmets</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Leonardi</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>DMR</given-names>
              </name>
              <name>
                <surname>Gelfand</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Lichten</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>NN</given-names>
              </name>
              <name>
                <surname>Armstrong</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Connor</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cordoro</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Elewski</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Gottlieb</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Kavanaugh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kivelevitch</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kiselica</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Korman</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Kroshinsky</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lebwohl</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Paller</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Parra</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Pathy</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Prater</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Rupani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Siegel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stoff</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Strober</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Hariharan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Menter</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>80</volume>
            <issue>4</issue>
            <fpage>1073</fpage>
            <page-range>1073-1113</page-range>
            <pub-id pub-id-type="pmid">30772097</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151612.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lamb</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Fried</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Giving patients 'perceived control' over psoriasis: advice for optimizing the physician-patient relationship.</article-title>
            <source>J Dermatolog Treat</source>
            <year>2004</year>
            <month>Jun</month>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>182</fpage>
            <page-range>182-4</page-range>
            <pub-id pub-id-type="pmid">15204152</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
